Multiple Sclerosis Trial, Recruiting NCT05051618 Sponsor: University of Illinois at Chicago Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Multiple Sclerosis Trial, Recruiting

NCT05051618
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been officially diagnosed with Multiple Sclerosis (MS)
  • You have been diagnosed with Major Depressive Disorder (MDD), confirmed through a structured interview
  • English is your primary language
  • You are between 18 and 64 years old
  • You have not had an MS relapse or taken steroids in the past 30 days
  • You have access to the internet and email
  • You are willing to complete questionnaires, wear a physical activity tracker, be randomly assigned to a study group, and take part in exercise testing

Who may not be able to join:

  • You are already meeting recommended physical activity guidelines (confirmed with trial site)
  • You have more than mild difficulty walking, as measured by a standard walking ability scale
  • Your depression symptoms are very mild or minimal, based on a standard depression questionnaire score
  • You answered "yes" to more than one question on a standard physical activity safety screening tool, which may indicate a higher risk of injury during strenuous exercise
  • You have significant difficulties with memory or following instructions, based on a telephone cognitive assessment
  • You have another serious mental health condition such as bipolar disorder, schizophrenia, obsessive-compulsive disorder, or other psychotic disorders, as these would require more intensive mental health care than this trial provides

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Robert W Motl, PhD, University of Illinois at Chicago

Phone: 205-975-1306

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Illinois at Chicago
Registry
ClinicalTrials.gov
Start date
1 April 2023
Est. completion
31 October 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in Depression Severity (self-report); Change in Depression Severity (observer-rated)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov